APA (7th ed.) Citation

Lu, H., Zheng, C., Xiong, B., & Xia, X. (2023). TACE versus TACE + entecavir versus TACE + tenofovir in the treatment of HBV associated hepatocellular carcinoma. BMC Cancer, 23(1), 1. https://doi.org/10.1186/s12885-023-10694-9

Chicago Style (17th ed.) Citation

Lu, Haohao, Chuansheng Zheng, Bin Xiong, and Xiangwen Xia. "TACE Versus TACE + entecavir Versus TACE + tenofovir in the Treatment of HBV Associated Hepatocellular Carcinoma." BMC Cancer 23, no. 1 (2023): 1. https://doi.org/10.1186/s12885-023-10694-9.

MLA (9th ed.) Citation

Lu, Haohao, et al. "TACE Versus TACE + entecavir Versus TACE + tenofovir in the Treatment of HBV Associated Hepatocellular Carcinoma." BMC Cancer, vol. 23, no. 1, 2023, p. 1, https://doi.org/10.1186/s12885-023-10694-9.